Pfizer Inc and BioNTech SE have stated that their COVID-19 vaccine evoked a strong immune response in children aged 5 to 11 years. They further stated that they intend to seek authorization for use of the vaccine in this age group in the United States, Europe and other places as early as possible.

It has been reported that the vaccine induced an immune response, in children 5 to 11 years of age, in Phase II/III clinical trial, which matched the response seen previously among 16-to-25 year olds. The safety profile of the vaccine was found to be comparable to the older age group as well.

Children in the 5 to 11 years age group received two doses of a 10 microgram dose of the vaccine, which is a third of the dose given to individuals aged 12 and older… (ET Healthworld – Reuters, September 20, 2021)